Globus Medical, Inc. (NYSE:GMED) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts rate Globus Medical a “Moderate Buy”: Nine of 17 analysts recommend buying the stock, two recommend a strong buy and six rate it a hold. The average 12-month price target is approximately $101.77, versus shares recently trading near $82.20.
• Quarterly results exceeded expectations: Globus Medical reported adjusted EPS of $1.34 and revenue of $789.6 million, surpassing estimates of $1.10 and $782.9 million, respectively. Revenue rose 5.9% year over year.
• Profit guidance increased, but revenue expectations and execution risks remain: Management raised fiscal 2026 EPS guidance to $4.95–$5.05 while maintaining revenue guidance near $3.2 billion. Analysts cited spine-market growth and margin improvements, but cautioned about risks involving Nevro and Enabling Technologies.

Globus Medical, Inc. (NYSE:GMED - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $101.7692.

A number of brokerages have weighed in on GMED. Truist Financial cut their price objective on shares of Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Thursday, July 16th. Wall Street Zen cut Globus Medical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 9th. UBS Group initiated coverage on Globus Medical in a report on Tuesday, July 28th. They set a "neutral" rating and a $82.00 price target on the stock. Piper Sandler dropped their price objective on Globus Medical from $115.00 to $100.00 and set an "overweight" rating on the stock in a research report on Monday, June 15th. Finally, Needham & Company LLC boosted their target price on Globus Medical from $114.00 to $117.00 and gave the stock a "buy" rating in a research report on Friday, May 8th.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

Globus Medical Stock Down 0.2%

Shares of NYSE:GMED opened at $82.20 on Monday. The stock has a market cap of $11.16 billion, a PE ratio of 21.02, a PEG ratio of 1.61 and a beta of 0.95. The company's fifty day moving average is $79.33 and its 200 day moving average is $85.17. Globus Medical has a 52 week low of $54.15 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.24. The business had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.Globus Medical's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the company earned $0.86 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts anticipate that Globus Medical will post 5 EPS for the current year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business's stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 18.38% of the company's stock.

Hedge Funds Weigh In On Globus Medical

Institutional investors and hedge funds have recently modified their holdings of the company. Annex Advisory Services LLC purchased a new stake in Globus Medical in the fourth quarter worth about $20,572,000. Northwestern Mutual Wealth Management Co. lifted its holdings in Globus Medical by 71,618.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company's stock worth $62,555,000 after purchasing an additional 715,470 shares in the last quarter. Lecap Asset Management Ltd. bought a new position in shares of Globus Medical during the fourth quarter worth $1,203,000. WCM Investment Management LLC purchased a new position in shares of Globus Medical during the first quarter valued at about $16,965,000. Finally, SG Americas Securities LLC grew its holdings in Globus Medical by 241.1% during the 1st quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company's stock valued at $29,333,000 after buying an additional 240,642 shares in the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source